Considering that DNA‐PKcs inhibitors have been utilized in several clinical trials for cancer treatment,[42] it appears promising to explore the application of DNA‐PKcs inhibitors in the treatment of metabolic disorder‐related cardiac dysfunction. The gene discussed is PRKDC; the disease is cancer.